180 results about "Virus vaccine" patented technology

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV-75 and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-75, has the preservation number of CCTCC NO: V2024114, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV DQ and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-DQ, has the preservation number of CCTCC NO: V2024113, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention relates to the field of biological medicine, in particular to an anti-tumor or anti-virus vaccine with IL-9 as an adjuvant. The invention provides a medicine and / or vaccine for preventing and treating diseases, the medicine and / or vaccine comprises IL-9 and a specific antigen, and experimental results show that compared with other cytokines, IL-9 can significantly enhance the cell and humoral immune intensity induced by antigens such as viruses and tumors, promote immune memory formation and improve the antibody level in serum; compared with vaccines without IL-9, protein vaccines, DNA vaccines or RNA vaccines containing IL-9 can significantly improve the prevention and treatment effect on viruses or tumors, and have wide application prospects in prevention and treatment of diseases caused by tumors, viruses, pathogenic bacteria and the like.

The invention discloses a preparation method and application of porcine pseudorabies virus multi-epitope polypeptide, and belongs to the technical field of veterinary biological products. The multi-epitope polypeptide comprises a cytotoxic T cell epitope, a helper T cell epitope and a linear B cell epitope; the cell epitopes are screened from key immunogenic proteins of the pseudorabies virus by using an immunoinformatics method. The porcine pseudorabies virus multi-epitope polypeptide designed by the invention is high in safety, has better antigenicity and physicochemical properties, can be efficiently expressed, and can be recognized by a pseudorabies virus specific antibody. By applying the porcine pseudorabies virus multi-epitope polypeptide, high-level specific antibodies and cellular immune response can be continuously induced to generate, strong protective efficacy is generated, and mice can be protected from death when infected with a lethal dose of porcine pseudorabies virus. Therefore, the multi-epitope polypeptide disclosed by the invention can be used as an alternative antigen of a porcine pseudorabies virus vaccine, the use of active virus is avoided, and a tool is provided for eradication of porcine pseudorabies virus.

The invention relates to the technical field of biological medicine, and discloses a culture medium for human metapneumovirus and application, the culture medium comprises the following components by mass: 850-920 parts of a basic culture medium; the metabolism reprogramming module is prepared from the following components in parts by weight: 0.05 to 0.15 part of 5-methyltetrahydrofolic acid, 0.3 to 0.7 part of N-acetyl-D-mannosamine and 1.0 to 3.0 parts of sodium dichloroacetate; the immune regulation and control module is prepared from 0.005 to 0.015 part of an RIG-I / MAVS pathway inhibitor; the receptor induction module is prepared from 0.5 to 1.5 parts of all-trans retinoic acid; the redox balance module is prepared from the following components in parts by weight: 0.1 to 0.5 part of pegylated superoxide dismutase and 0.002 to 0.008 part of sodium selenite. According to the method, the proportion of infectious virus particles can be remarkably increased, the generation of defective particles is reduced, meanwhile, the production cycle of host cells is prolonged, large-scale continuous culture is supported, and a high-quality and high-efficiency solution is provided for industrial production of gene therapy vectors and virus vaccines.

The invention belongs to the technical field of biological medicine, and discloses an application of recombinant protein in preparation of a snakehead vesicular virus vaccine. A G protein of a snakehead vesicular virus (SHVV) is taken as an antigen for the vaccine, recombinant escherichia coli BL21 (pET32a-G) capable of expressing the protein is constructed by utilizing a genetic engineering technical means, recombinant protein rG is obtained through induced expression, and the nano-carrier vaccine (BNC-rG vaccine) of the snakehead vesicular virus is prepared by taking bacterial nano-cellulose as a carrier. According to the BNC-rG vaccine provided by the invention, immune protection against SHVV can be realized through immersion immunization, the specific antibody level is remarkably improved, the relative protection rate of snakehead reaches 80.00% after snakehead is infected with SHVV after immersion immunization for 4 weeks, and the immune protection effect is remarkable.

The present disclosure relates to field of lyophilized / freeze-dried viral vaccine composition and methods for manufacturing and obtaining the vaccine composition comprising live attenuated flavivirus as vaccine antigen selected from a group of yellow fever virus, dengue virus, Japanese encephalitis (JE) virus, Kunjin virus, West Nile (WN) virus, tick-borne encephalitis (TBE) virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, Zika virus vaccine antigen; and stabilizers comprising sugar or sugar alcohol; amino acids; lactalbumin hydrolysate and gelatin. Post reconstitution, the composition preserves the desired characteristics of the virus, including immunogenicity and stability. The composition of the present disclosure can be safely administered subcutaneously or intramuscularly such that the vaccine composition induces complete immune response to yellow fever virus infectious agent and meets the criterion for the seroprotection for the said immunogenic components comprising yellow fever virus.

The invention provides an influenza vaccine adjuvant based on lentinan as well as a preparation method and application thereof. The active ingredient of the vaccine adjuvant is lentinan, the lentinan is extracted from fresh lentinus edodes through a water extraction and alcohol precipitation method, no additional chemical modification is needed, the vaccine adjuvant can be used for preparing the influenza virus vaccine, and the influenza virus vaccine at least contains one of three inactivated influenza virus antigens, namely H1N1 A, H3N2 A and Victoria B. The invention also provides a vaccine preparation and a preparation method thereof, the vaccine preparation comprises the vaccine adjuvant and an influenza virus vaccine, the content of lentinan in the vaccine preparation is 4 mg / mL, and the vaccine preparation has an immunological enhancement effect.

The invention discloses a recombinant yeast for expressing large yellow croaker iridovirus MCP protein and a preparation method and application of the recombinant yeast in preparation of vaccines, and is characterized in that the recombinant yeast is saccharomyces cerevisiae transformed with pYD1-MCP recombinant plasmids and is named as EBY100 / pYD1-MCP, the pYD1-MCP recombinant plasmids can express the MCP protein on a yeast surface display system, the nucleotide sequence of a gene segment of the MCP protein is shown as SEQ ID NO.1, the nucleotide sequence of the gene segment of the MCP protein is shown as SEQ ID NO.2, and the nucleotide sequence of the gene segment of the MCP protein is shown as SEQ ID NO.2. The preparation method comprises a step of constructing a recombinant plasmid pYD1-MCP and a step of constructing a recombinant yeast EBY100 / pYD1-MCP, the oral vaccine of the larimichthys crocea iridovirus vaccine can be prepared, and the oral vaccine has the advantages of being high in protection rate, safe, low in cost, convenient to use and good in application prospect in prevention and control of the larimichthys crocea iridovirus.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention relates to the technical field of biology, in particular to a respiratory syncytial virus culture medium, a respiratory syncytial virus antigen and a preparation method and application of the respiratory syncytial virus antigen. The respiratory syncytial virus antigen obtained by the respiratory syncytial virus culture medium and the preparation method is high in activity, is suitable for large-scale production, and can be used for preparing respiratory syncytial virus vaccines; and / or preparing a reagent and / or a kit for detecting the anti-respiratory syncytial virus specific IgM antibody, thereby laying a foundation for the development of RSV vaccines and the detection of serological specific antibodies.

The present invention relates to a novel vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). According to the invention, after the SFTSV vaccine is injected in vivo, the formation speed of Gn and Gc proteins can be obviously accelerated. Besides, the vaccine can effectively stimulate humoral immune response, for example, a specific neutralizing antibody aiming at a virus antigen is induced to generate, so that a remarkable protection effect aiming at SFTSV is provided for an individual.

The invention discloses a dual fluorescent quantitative PCR (polymerase chain reaction) primer probe combination for identifying a PRV (pseudorabies virus) vaccine strain and a wild strain. The dual fluorescent quantitative PCR primer probe combination comprises two pairs of primers gB-F and gB-R, gE-F and gE-R, and probes gB-probe and gE-probe, wherein the two pairs of primers are used for specifically amplifying a PRV gB gene and a PRV gE gene; through existence of real-time fluorescence PCR amplification curves of the PRV gB gene and the gE gene, a PRV vaccine strain (gE gene deletion) and a wild strain can be rapidly, specifically, sensitively and stably identified, technical support can be provided for porcine pseudorabies epidemic disease monitoring, and thorough purification of the PRV in a live pig breeding link is facilitated.

The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

A chimeric nucleotide sequence that corresponds to an encoded fusion protein comprising a polyepitope resulting from selecting and juxtaposing multiple epitopes from a coronavirus protein to induce an immune response in mammals. In one embodiment, said fusion protein comprises: a) a first peptide consisting of epitopes found in the amino acid sequence of replicase polyprotein 1ab (PR1ab); b) a first spacer; c) a modified form of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD). In one embodiment, the replicase polyprotein is defined by SEQ ID NO: 96 flanked by a gD fragment comprising the amino acid sequence defined by SEQ ID NO: 98 in the N-terminal portion and another gD fragment comprising the amino acid sequence defined by SEQ ID NO: 100 in the C-terminal region. Use of the fusion protein has surprising results in inducing cellular and humoral immune responses against coronavirus, SARS-COV-2, and related viruses.

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.

The invention relates to a primer-probe set, comprising a forward primer having the nucleotide sequence of SEQ ID NO:1 and a reverse primer having the nucleotide sequence of SEQ ID NO:2, and a peptide nucleic acid (PNA) probe having the sequence of HEX-OO-(SEQ ID NO:3)-Lysine-BHQ1, which are used for differentiating the Peste des Petits Ruminants (PPR) virus vaccine and field strains and for preventing false positive results arising from the PPR vaccine, as well as to their operating temperatures. Said primer-probe set can differentiate between the vaccine strain containing the nucleotide sequence of SEQ ID NO:4 and the field strain containing the nucleotide sequence of SEQ ID NO:5. Thus, by means of said primer-probe set, false positive results arising from the PPR vaccine are prevented, and accordingly, unnecessary quarantine measures are also avoided.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

Comprising a multivalent fusion protein and an exosome delivery carrier, and the content of the multivalent fusion protein is 70-90 [mu] g; wherein the multivalent fusion protein is a fusion protein formed by connecting a gB glycoprotein, a gC glycoprotein, a gD glycoprotein and a high-immunogenicity part of an important antigen segment selected from gE and gI; the exosome delivery carrier is a small vesicle extracted and purified from mesenchymal stem cells or HEK 293-F cells, the surface of the exosome delivery carrier is modified with a CD40L single-chain antibody, and the exosome delivery carrier is used for loading multivalent fusion protein; the porcine pseudorabies virus vaccine further comprises adjuvants, and the adjuvants comprise a TLR agonist, CpG oligonucleotide, synthetic liposome and a traditional aluminum salt adjuvant. The porcine pseudorabies virus vaccine also comprises a mucous membrane adsorbent, a penetration enhancer, a stabilizer and a preservative. The invention aims to construct a multivalent fusion protein complex containing a plurality of important antigen segments by using an advanced bioengineering technology, and provides a wider protection effect by combining an efficient exosome delivery platform and a method for enhancing immune response.

Provided herein are a respiratory syncytial virus (RSV) vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding RSV mutant F B strain protein, and optionally a mRNA including an ORF encoding RSV mutant F A strain protein, and a method of inducing immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Provided herein are also a respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition including a mRNA including an ORF encoding RSV mutant F A strain protein, a mRNA including an ORF encoding RSV mutant F B strain protein, and a mRNA including an ORF encoding hMPV F protein, and a method of inducing immune response against RSV and hMPV by administering an effective amount of the RSV and hMPV vaccine composition to a subject in need thereof.

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The present invention provides a novel attenuated strain of goose parvovirus and its construction method and application, belonging to the field of virus vaccines. The present invention has determined two artificial attenuation sites that weaken the virulence of the novel goose parvovirus through research. The NGPV-NMG50 attenuated strain obtained in this application is used as a live vaccine prepared as an immunogen, and the feather loss protection rate of ducks can reach 100% without the addition of adjuvants. The minimum lethal dose of the virus is determined by diluting the NMG21 wild strain in multiples, and then the optimal immune dose of the NGPV-NMG50 attenuated strain is screened, and the optimal immune dose results of the NGPV-NMG50 attenuated strain in clinical use are obtained, so that ducklings can effectively establish an immune barrier against the novel goose parvovirus.

The invention relates to a cherry valley duck PLV virus vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus immunity. The vaccine is prepared by taking a Parry's Lagon virus (PLV) virus strain PLV-20155 as an immunogen, the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46296. The invention further discloses a preparation method of the vaccine. The vaccine is a PLV-20155 virus inactivated vaccine, and the preparation method of the vaccine comprises the following steps: inoculating the PLV-20155 virus into an SPF chick embryo for propagation, harvesting a virus liquid, inactivating with formaldehyde, verifying safety, emulsifying with white oil to prepare the vaccine and the like. In addition, the vaccine disclosed by the invention can be used for effectively preventing diseases such as laying rate reduction, follicle necrosis and fallopian tube atrophy of the cherry valley ducks caused by the PLV-20155 virus, and the economic benefit of breeding is remarkably improved.

The present invention relates to the field of medicine, and specifically discloses an influenza virus vaccine fusion protein, which is a fusion protein formed by connecting an HA antigen fragment encoded by an influenza HA antigen gene and an M2 extracellular region fragment (M2e; Membrane Protein (M2) Extracellular Region (M2e) in series with an Fc fragment encoded by a human immunoglobulin gene in series. The fusion protein of the present invention has higher antigenicity than a single HA antigen or a single M2 extracellular region fragment antigen, and the Fc fragment can improve protein purification efficiency and prolong the half-life of the antigen in vivo. Therefore, the influenza vaccine provided by the present invention has great advantages and great application value.

The invention discloses a respiratory syncytial virus mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application of the respiratory syncytial virus mRNA vaccine. A proper promoter, 5 '-UTR, 3'-UTR and 3 '-terminal PolyA are selected to be combined into a complete sequence for coding RSV virus preF, then mRNA is obtained through synthesis, reverse transcription and purification, and two sequences which express preF protein in a cell level and have high stability and strong binding capacity with a neutralizing antibody are obtained through screening from five nucleic acid sequences giving consideration to the expression level and the stability; according to the mRNA vaccine provided by the invention, the components of the lipid nanoparticles are improved, and the expression of a target antigen in vivo is enhanced, so that the prepared mRNA vaccine can generate a strong and lasting immune effect after immunizing a mouse and has stronger protective force on viruses.

The application provides a varicella-zoster virus vaccine and application thereof, and belongs to the technical field of vaccines.The varicella-zoster virus vaccine comprises liposome nanoparticles, zoster virus glycoprotein E and an adjuvant encapsulated in the liposome nanoparticles.The adjuvant comprises triterpenoid saponins.In the application, the zoster virus glycoprotein E (gE) is wrapped by the liposome nanoparticles, which can effectively promote antigen-presenting cells to phagocytose and efficiently deliver the antigen, and realize sustained stimulation of the vaccine to the body to produce a specific cellular immune response against VZV-gE.The triterpenoid saponins used in the application can effectively realize cross-presentation of the antigen zoster virus glycoprotein E and induce an antigen-specific cellular immune response.In addition, the cholesterol rich in the liposome nanoparticles can effectively neutralize the cytotoxicity of the triterpenoid saponins, ensuring the safety of the vaccine.